Top

Current Nutrition Reports

Published in:

01-09-2019 | Insulins | Cardiovascular Disease (JHY Wu, Section Editor)

The Endocrine Role of Bone in Cardiometabolic Health

Authors: Rosemary DeLuccia, May Cheung, Rohit Ramadoss, Abeer Aljahdali, Deeptha Sukumar

Published in: Current Nutrition Reports | Issue 3/2019

Abstract

Purpose of Review

The purpose of this review is to discuss the current knowledge about major bone regulating hormones vitamin D, parathyroid hormone (PTH), estrogen and bone metabolism markers osteocalcin (OC), bone-specific alkaline phosphatase (BAP), N-terminal propeptide of type 1 collagen (P1NP), and c-terminal type 1 collagen (CTX) and their mechanistic effects on cardiometabolic health.

Recent Findings

Bone regulating hormones, nutrients, and turnover markers influence different aspects of cardiometabolic health including body composition, cardiovascular function, and glycemic control. While most observational research supports a relationship between bone as an endocrine organ and cardiometabolic outcomes, there are limited human clinical trials to strengthen a causal link between the two.

Summary

While the associations between bone and cardiometabolic health are beginning to be understood based on findings from large observations studies, further exploration of bone’s causal influence on health outcomes in humans and the underlying mechanisms of effect are necessary.

Fernandes TAP, Goncalves LML, Brito JAA. Relationships between bone turnover and energy metabolism. J Diabetes Res. 2017;2017:9021314. https://doi.org/10.1155/2017/9021314.CrossRefPubMedPubMedCentral

Oldknow KJ, MacRae VE, Farquharson C. Endocrine role of bone: recent and emerging perspectives beyond osteocalcin. J Endocrinol. 2015;225(1):R1–19. https://doi.org/10.1530/joe-14-0584.CrossRefPubMed

Suchacki KJ, Roberts F, Lovdel A, Farquharson C, Morton NM, MacRae VE, et al. Skeletal energy homeostasis: a paradigm of endocrine discovery. J Endocrinol. 2017;234(1):R67–r79. https://doi.org/10.1530/joe-17-0147.CrossRefPubMed

Sung CC, Liao MT, Lu KC, Wu CC. Role of vitamin D in insulin resistance. J Biomed Biotechnol. 2012;2012:634195. https://doi.org/10.1155/2012/634195.CrossRefPubMedPubMedCentral

Parker J, Hashmi O, Dutton D, Mavrodaris A, Stranges S, Kandala NB, et al. Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas. 2010;65(3):225–36. https://doi.org/10.1016/j.maturitas.2009.12.013.CrossRefPubMed

Parikh SJ, Edelman M, Uwaifo GI, Freedman RJ, Semega-Janneh M, Reynolds J, et al. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab. 2004;89(3):1196–9. https://doi.org/10.1210/jc.2003-031398.CrossRefPubMed

Salehpour A, Hosseinpanah F, Shidfar F, Vafa M, Razaghi M, Dehghani S, et al. A 12-week double-blind randomized clinical trial of vitamin D(3) supplementation on body fat mass in healthy overweight and obese women. Nutr J. 2012;11:78. https://doi.org/10.1186/1475-2891-11-78.CrossRefPubMedPubMedCentral

Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol. 2014;21(3):319–29. https://doi.org/10.1016/j.chembiol.2013.12.016.CrossRefPubMedPubMedCentral

Mason C, Tapsoba JD, Duggan C, Imayama I, Wang CY, Korde L, et al. Effects of vitamin D3 supplementation on lean mass, muscle strength, and bone mineral density during weight loss: a double-blind randomized controlled trial. J Am Geriatr Soc. 2016;64(4):769–78. https://doi.org/10.1111/jgs.14049.CrossRefPubMedPubMedCentral

10•.

Bislev LS, Langagergaard Rodbro L, Rolighed L, Sikjaer T, Rejnmark L. Effects of vitamin D3 supplementation on muscle strength, mass, and physical performance in women with vitamin D insufficiency: a randomized placebo-controlled trial. Calcif Tissue Int. 2018. https://doi.org/10.1007/s00223-018-0443-z. This randomized placebo-controlled trial examined the effects of vitamin D3 supplementation on muscle strength, physical performance, postural stability, well-being, and quality of life in healthy postmenopausal women with poor vitamin D status, and determined nonsignificant unfavorable outcomes of vitamin D3 supplementation on muscle strength and physical performance, and no beneficial effects on any additional outcomes.

11.

Szlagatys-Sidorkiewicz A, Brzezinski M, Jankowska A, Metelska P, Slominska-Fraczek M, Socha P. Long-term effects of vitamin D supplementation in vitamin D deficient obese children participating in an integrated weight-loss programme (a double-blind placebo-controlled study) - rationale for the study design. BMC Pediatr. 2017;17(1):97. https://doi.org/10.1186/s12887-017-0851-7.CrossRefPubMedPubMedCentral

12•.

Karefylakis C, Sarnblad S, Ariander A, Ehlersson G, Rask E, Rask P. Effect of Vitamin D supplementation on body composition and cardiorespiratory fitness in overweight men-a randomized controlled trial. Endocrine. 2018;61(3):388–97. https://doi.org/10.1007/s12020-018-1665-6. This prospective placebo-controlled, double blinded, randomized trial of overweight/obese men with vitamin D deficiency determined that 2000 IU of cholecalciferol given over 6 months resulted in no significant improvements in body composition.CrossRefPubMedPubMedCentral

13.

Strange RC, Shipman KE, Ramachandran S. Metabolic syndrome: a review of the role of vitamin D in mediating susceptibility and outcome. World J Diabetes. 2015;6(7):896–911. https://doi.org/10.4239/wjd.v6.i7.896.CrossRefPubMedPubMedCentral

14.

Mitri J, Dawson-Hughes B, Hu FB, Pittas AG. Effects of vitamin D and calcium supplementation on pancreatic beta cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the calcium and vitamin D for diabetes mellitus (CaDDM) randomized controlled trial. Am J Clin Nutr. 2011;94(2):486–94. https://doi.org/10.3945/ajcn.111.011684.CrossRefPubMedPubMedCentral

15.

Nagpal J, Pande JN, Bhartia A. A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med. 2009;26(1):19–27. https://doi.org/10.1111/j.1464-5491.2008.02636.x.CrossRefPubMed

16•.

Trummer C, Theiler-Schwetz V, Kollmann M, Wolfler M, Munzker J, Pilz S, et al. Effects of vitamin D supplementation on metabolic and endocrine parameters in healthy premenopausal women: a randomized controlled trial. Clin Nutr (Edinburgh, Scotland). 2019. https://doi.org/10.1016/j.clnu.2019.03.007. This double-blind, randomized placebo-controlled trial conducted in premenopausal women with poor vitamin D status determined that 20,000 IU of cholecalciferol given over 24 weeks resulted in a significant effect on the homeostatic model assessment-insulin resistance (HOMA-IR) and the quantitative-insulin-sensitivity check index (QUICKI), supporting improved endocrine functioning.

17.

George PS, Pearson ER, Witham MD. Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. Diabet Med. 2012;29(8):e142–50. https://doi.org/10.1111/j.1464-5491.2012.03672.x.CrossRefPubMed

18.

Legarth C, Grimm D, Wehland M, Bauer J, Kruger M. The Impact of Vitamin D in the Treatment of Essential Hypertension. International journal of molecular sciences. 2018;19(2). https://doi.org/10.3390/ijms19020455.

19.

Chen S, Sun Y, Agrawal DK. Vitamin D deficiency and essential hypertension. J Am Soc Hypertens. 2015;9(11):885–901. https://doi.org/10.1016/j.jash.2015.08.009.CrossRefPubMedPubMedCentral

20.

Elamin MB, Abu Elnour NO, Elamin KB, Fatourechi MM, Alkatib AA, Almandoz JP, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96(7):1931–42. https://doi.org/10.1210/jc.2011-0398.CrossRefPubMed

21.

Beveridge LA, Struthers AD, Khan F, Jorde R, Scragg R, Macdonald HM, et al. Effect of vitamin D supplementation on blood pressure: a systematic review and meta-analysis incorporating individual patient data. JAMA Intern Med. 2015;175(5):745–54. https://doi.org/10.1001/jamainternmed.2015.0237.CrossRefPubMedPubMedCentral

22.

Kassi E, Adamopoulos C, Basdra EK, Papavassiliou AG. Role of vitamin D in atherosclerosis. Circulation. 2013;128(23):2517–31. https://doi.org/10.1161/circulationaha.113.002654.CrossRefPubMed

23.

Skaaby T, Husemoen LL, Martinussen T, Thyssen JP, Melgaard M, Thuesen BH, et al. Vitamin D status, filaggrin genotype, and cardiovascular risk factors: a Mendelian randomization approach. PLoS One. 2013;8(2):e57647. https://doi.org/10.1371/journal.pone.0057647.CrossRefPubMedPubMedCentral

24.

Favus MJ, Goltzman D. Regulation of calcium and magnesium. Hoboken: John Wiley & Sons, Inc.; 2013.CrossRef

25.

Nissenson RAJ, Juppner H. Parathyroid Hormone. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Hoboken: John Wiley & Sons, Inc.; 2013. p. 208–14.CrossRef

26.

Potts JT. Parathyroid hormone: past and present. J Endocrinol. 2005;187(3):311–25. https://doi.org/10.1677/joe.1.06057.CrossRefPubMed

27.

Bikle DD. Vitamin D and bone. Curr Osteoporos Rep. 2012;10(2):151–9. https://doi.org/10.1007/s11914-012-0098-z.CrossRefPubMedPubMedCentral

28.

Cannata-Andia JB, Carrera F. The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS. NDT Plus. 2008;1(Suppl 1):i2–6. https://doi.org/10.1093/ndtplus/sfm037.CrossRefPubMedPubMedCentral

29.

Rashid G, Bernheim J, Green J, Benchetrit S. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am J Physiol Ren Physiol. 2007;292(4):F1215–8. https://doi.org/10.1152/ajprenal.00406.2006.CrossRef

30.

Bell NH, Epstein S, Greene A, Shary J, Oexmann MJ, Shaw S. Evidence for alteration of the vitamin D-endocrine system in obese subjects. J Clin Invest. 1985;76(1):370–3. https://doi.org/10.1172/jci111971.CrossRefPubMedPubMedCentral

31.

Bolland MJ, Grey AB, Ames RW, Horne AM, Gamble GD, Reid IR. Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. Bone. 2006;38(3):317–21. https://doi.org/10.1016/j.bone.2005.08.018.CrossRefPubMed

32.

Saab G, Whaley-Connell A, McFarlane SI, Li S, Chen SC, Sowers JR, et al. Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease. Metab Clin Exp. 2010;59(3):385–9. https://doi.org/10.1016/j.metabol.2009.08.007.CrossRefPubMed

33.

Marwaha RK, Garg MK, Mahalle N, Bhadra K, Tandon N. Role of parathyroid hormone in determination of fat mass in patients with vitamin D deficiency. Indian J Endocrinol Metabol. 2017;21(6):848–53. https://doi.org/10.4103/ijem.IJEM_42_17.CrossRef

34.

Querfeld U, Hoffmann MM, Klaus G, Eifinger F, Ackerschott M, Michalk D, et al. Antagonistic effects of vitamin D and parathyroid hormone on lipoprotein lipase in cultured adipocytes. J Am Soc Nephrol. 1999;10(10):2158–64.PubMed

35.

Reusch JE, Sussman KE, Draznin B. Inverse relationship between GLUT-4 phosphorylation and its intrinsic activity. J Biol Chem. 1993;268(5):3348–51.PubMed

36.

Lotito A, Teramoto M, Cheung M, Becker K, Sukumar D. Serum parathyroid hormone responses to vitamin D supplementation in overweight/obese adults: a systematic review and meta-analysis of randomized clinical trials. Nutrients. 2017;9(3). https://doi.org/10.3390/nu9030241.

37.

Lotfi-Dizaji L, Mahboob S, Aliashrafi S, Vaghef-Mehrabany E, Ebrahimi-Mameghani M, Morovati A. Effect of vitamin D supplementation along with weight loss diet on meta-inflammation and fat mass in obese subjects with vitamin D deficiency: a double-blind placebo-controlled randomized clinical trial. Clin Endocrinol. 2019;90(1):94–101. https://doi.org/10.1111/cen.13861.CrossRef

38•.

Valente-Da-Silva HG, Maya MCA, Moreira AS. Parathyroidectomy in chronic kidney disease: effects on weight gain and on quality of life improvement. Revista do Colegio Brasileiro de Cirurgioes. 2017;44(3):263–9. https://doi.org/10.1590/0100-69912017003007. This longitudinal study of hemodialysis patients with severe secondary parathyroidism demonstrated that parathyroidectomy resulted in significant increases in body weight and body cell mass with stabilization of intact parathyroid hormone concentrations after surgery.CrossRefPubMed

39.

Gunther CW, Legowski PA, Lyle RM, Weaver CM, McCabe LD, McCabe GP, et al. Parathyroid hormone is associated with decreased fat mass in young healthy women. Int J Obes. 2006;30(1):94–9. https://doi.org/10.1038/sj.ijo.0803066.CrossRef

40.

Ishimura E, Okuno S, Tsuboniwa N, Norimine K, Fukumoto S, Yamakawa K, et al. Significant positive association between parathyroid hormone and fat mass and lean mass in chronic hemodialysis patients. J Clin Endocrinol Metab. 2013;98(3):1264–70. https://doi.org/10.1210/jc.2012-3883.CrossRefPubMed

41.

Kimura S, Yoshioka K. Parathyroid hormone and parathyroid hormone type-1 receptor accelerate myocyte differentiation. Sci Rep. 2014;4:5066. https://doi.org/10.1038/srep05066.CrossRefPubMedPubMedCentral

42.

Visser M, Deeg DJ, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab. 2003;88(12):5766–72. https://doi.org/10.1210/jc.2003-030604.CrossRefPubMed

43.

Pilz S, Tomaschitz A, Drechsler C, Ritz E, Boehm BO, Grammer TB, et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J. 2010;31(13):1591–8. https://doi.org/10.1093/eurheartj/ehq109.CrossRefPubMed

44.

Morley P, Whitfield JF, Willick GE. Parathyroid hormone: an anabolic treatment for osteoporosis. Curr Pharm Des. 2001;7(8):671–87.CrossRefPubMed

45.

Goettsch C, Iwata H, Aikawa E. Parathyroid hormone: critical bridge between bone metabolism and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2014;34(7):1333–5. https://doi.org/10.1161/atvbaha.114.303637.CrossRefPubMedPubMedCentral

46.

Coen G, Calabria S, Bellinghieri G, Pecchini F, Conte F, Chiappini MG, et al. Parathyroidectomy in chronic renal failure: short- and long-term results on parathyroid function, blood pressure and anemia. Nephron. 2001;88(2):149–55. https://doi.org/10.1159/000045976.CrossRefPubMed

47.

Heyliger A, Tangpricha V, Weber C, Sharma J. Parathyroidectomy decreases systolic and diastolic blood pressure in hypertensive patients with primary hyperparathyroidism. Surgery. 2009;146(6):1042–7. https://doi.org/10.1016/j.surg.2009.09.024.CrossRefPubMed

48.

Ishay A, Herer P, Luboshitzky R. Effects of successful parathyroidectomy on metabolic cardiovascular risk factors in patients with severe primary hyperparathyroidism. Endocr Pract. 2011;17(4):584–90. https://doi.org/10.4158/ep10321.Or.CrossRefPubMed

49.

Akpunonu BE, Mulrow PJ, Hoffman EA. Secondary hypertension: evaluation and treatment. Dis Mon. 1996;42(10):609–722.CrossRefPubMed

50.

Brown J, de Boer IH, Robinson-Cohen C, Siscovick DS, Kestenbaum B, Allison M, et al. Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosis. J Clin Endocrinol Metab. 2015;100(2):490–9. https://doi.org/10.1210/jc.2014-3949.CrossRefPubMed

51.

Maniero C, Fassina A, Seccia TM, Toniato A, Iacobone M, Plebani M, et al. Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. J Hypertens. 2012;30(2):390–5. https://doi.org/10.1097/HJH.0b013e32834f0451.CrossRefPubMed

52.

Pilz S, Kienreich K, Drechsler C, Ritz E, Fahrleitner-Pammer A, Gaksch M, et al. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab. 2012;97(1):E75–9. https://doi.org/10.1210/jc.2011-2183.CrossRefPubMed

53.

Rossi E, Sani C, Perazzoli F, Casoli MC, Negro A, Dotti C. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens. 1995;8(9):884–93. https://doi.org/10.1016/0895-7061(95)00182-o.CrossRefPubMed

54.

Neves KR, Graciolli FG, dos Reis LM, Graciolli RG, Neves CL, Magalhaes AO, et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int. 2007;71(12):1262–70. https://doi.org/10.1038/sj.ki.5002241.CrossRefPubMed

55.

Nilsson IL, Rastad J, Johansson K, Lind L. Endothelial vasodilatory function and blood pressure response to local and systemic hypercalcemia. Surgery. 2001;130(6):986–90. https://doi.org/10.1067/msy.2001.118368.CrossRefPubMed

56.

Rambausek M, Ritz E, Rascher W, Kreusser W, Mann JF, Kreye VA, et al. Vascular effects of parathyroid hormone (PTH). Adv Exp Med Biol. 1982;151:619–32.CrossRefPubMed

57.

Fliser D, Franek E, Fode P, Stefanski A, Schmitt CP, Lyons M, et al. Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant. 1997;12(5):933–8.CrossRefPubMed

58.

Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab. 2001;86(4):1633–7. https://doi.org/10.1210/jcem.86.4.7393.CrossRefPubMed

59.

Pilz S, Gaksch M, Kienreich K, Grubler M, Verheyen N, Fahrleitner-Pammer A, et al. Effects of vitamin D on blood pressure and cardiovascular risk factors: a randomized controlled trial. Hypertension (Dallas, Tex : 1979). 2015;65(6):1195–201. https://doi.org/10.1161/hypertensionaha.115.05319.CrossRef

60.

Wannamethee SG, Welsh P, Papacosta O, Lennon L, Whincup PH, Sattar N. Elevated parathyroid hormone, but not vitamin D deficiency, is associated with increased risk of heart failure in older men with and without cardiovascular disease. Circ Heart Fail. 2014;7(5):732–9. https://doi.org/10.1161/circheartfailure.114.001272.CrossRefPubMed

61.

van Hoek M, Dallinga-Thie GM, Steyerberg EW, Sijbrands EJ. Diagnostic value of post-heparin lipase testing in detecting common genetic variants in the LPL and LIPC genes. Eur J Hum Genet. 2009;17(11):1386–93. https://doi.org/10.1038/ejhg.2009.61.CrossRefPubMedPubMedCentral

62.

Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013;5(4):1218–40. https://doi.org/10.3390/nu5041218.CrossRefPubMedPubMedCentral

63.

Parfitt AM. The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone diseases. II. PTH and bone cells: bone turnover and plasma calcium regulation. Metab Clin Exp. 1976;25(8):909–55.CrossRefPubMed

64.

Hagstrom E, Lundgren E, Rastad J, Hellman P. Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur J Endocrinol. 2006;155(1):33–9. https://doi.org/10.1530/eje.1.02173.CrossRefPubMed

65.

Zanos S, Mitsopoulos E, Sakellariou G. Parathyroid hormone levels, calcium-channel blockers, and the dyslipidemia of nondiabetic hemodialysis patients. Ren Fail. 2005;27(2):163–9.CrossRefPubMed

66.

Norenstedt S, Pernow Y, Brismar K, Saaf M, Ekip A, Granath F, et al. Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study. Eur J Endocrinol. 2013;169(6):795–804. https://doi.org/10.1530/eje-13-0547.CrossRefPubMedPubMedCentral

67.

Rolighed L, Rejnmark L, Sikjaer T, Heickendorff L, Vestergaard P, Mosekilde L, et al. Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J Clin Endocrinol Metab. 2014;99(3):1072–80. https://doi.org/10.1210/jc.2013-3978.CrossRefPubMed

68.

Shah VN, Shah CS, Bhadada SK, Rao DS. Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature. Clin Endocrinol. 2014;80(6):797–803. https://doi.org/10.1111/cen.12398.CrossRef

69.

Jorde R, Szumlas K, Haug E, Sundsfjord J. The effects of calcium supplementation to patients with primary hyperparathyroidism and a low calcium intake. Eur J Nutr. 2002;41(6):258–63. https://doi.org/10.1007/s00394-002-0383-1.CrossRefPubMed

70.

Richards ML, Thompson NW. Diabetes mellitus with hyperparathyroidism: another indication for parathyroidectomy? Surgery. 1999;126(6):1160–6.CrossRefPubMed

71.

Schaerstrom R, Hamfelt A, Soderhjelm L. Parathyroid hormone and calcitonin in diabetes mellitus. Ups J Med Sci. 1986;91(1):99–104.CrossRefPubMed

72.

Wongsurawat N, Armbrecht HJ, Siegel NA. Effects of diabetes mellitus on parathyroid hormone-stimulated protein kinase activity, ferredoxin phosphorylation, and renal 1,25-dihydroxyvitamin D production. J Lab Clin Med. 1991;117(4):319–24.PubMed

73.

Fadda GZ, Akmal M, Lipson LG, Massry SG. Direct effect of parathyroid hormone on insulin secretion from pancreatic islets. Am J Phys. 1990;258(6 Pt 1):E975–84. https://doi.org/10.1152/ajpendo.1990.258.6.E975.CrossRef

74.

Saxe AW, Gibson G, Gingerich RL, Levy J. Parathyroid hormone decreases in vivo insulin effect on glucose utilization. Calcif Tissue Int. 1995;57(2):127–32.CrossRefPubMed

75.

Chang E, Donkin SS, Teegarden D. Parathyroid hormone suppresses insulin signaling in adipocytes. Mol Cell Endocrinol. 2009;307(1–2):77–82. https://doi.org/10.1016/j.mce.2009.03.024.CrossRefPubMedPubMedCentral

76.

Rhee CM, Leung AM, Kovesdy CP, Lynch KE, Brent GA, Kalantar-Zadeh K. Updates on the management of diabetes in dialysis patients. Semin Dial. 2014;27(2):135–45. https://doi.org/10.1111/sdi.12198.CrossRefPubMedPubMedCentral

77.

Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care. 2007;30(4):980–6. https://doi.org/10.2337/dc06-1994.CrossRefPubMed

78.

Meyer MR, Clegg DJ, Prossnitz ER, Barton M. Obesity, insulin resistance and diabetes: sex differences and role of oestrogen receptors. Acta Physiol (Oxford, England). 2011;203(1):259–69. https://doi.org/10.1111/j.1748-1716.2010.02237.x.CrossRef

79.

Wise PM, Suzuki S, Brown CM. Estradiol: a hormone with diverse and contradictory neuroprotective actions. Dialogues Clin Neurosci. 2009;11(3):297–303.PubMedPubMedCentral

80.

Vrtacnik P, Ostanek B, Mencej-Bedrac S, Marc J. The many faces of estrogen signaling. Biochem Med. 2014;24(3):329–42. https://doi.org/10.11613/bm.2014.035.CrossRef

81.

Oursler MJ, Osdoby P, Pyfferoen J, Riggs BL, Spelsberg TC. Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci U S A. 1991;88(15):6613–7.CrossRefPubMedPubMedCentral

82.

Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev. 2008;29(4):441–64. https://doi.org/10.1210/er.2008-0002.CrossRefPubMedPubMedCentral

83.

Kousteni S, Bellido T, Plotkin LI, O’Brien CA, Bodenner DL, Han L, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001;104(5):719–30.PubMed

84.

Quinton ND, Smith RF, Clayton PE, Gill MS, Shalet S, Justice SK, et al. Leptin binding activity changes with age: the link between leptin and puberty. J Clin Endocrinol Metab. 1999;84(7):2336–41. https://doi.org/10.1210/jcem.84.7.5834.CrossRefPubMed

85.

Ainslie DA, Morris MJ, Wittert G, Turnbull H, Proietto J, Thorburn AW. Estrogen deficiency causes central leptin insensitivity and increased hypothalamic neuropeptide Y. Int J Obes Relat Metab Disord. 2001;25(11):1680–8. https://doi.org/10.1038/sj.ijo.0801806.CrossRefPubMed

86.

Shi H, Clegg DJ. Sex differences in the regulation of body weight. Physiol Behav. 2009;97(2):199–204. https://doi.org/10.1016/j.physbeh.2009.02.017.CrossRefPubMedPubMedCentral

87.

Norman RJ, Flight IH, Rees MC. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. Cochrane Database Syst Rev. 2000;(2):Cd001018. https://doi.org/10.1002/14651858.Cd001018.

88.

Ziaei S, Moaya M, Faghihzadeh S. Comparative effects of continuous combined hormone therapy and tibolone on body composition in postmenopausal women. Climacteric. 2010;13(3):249–53. https://doi.org/10.3109/13697130903318240.CrossRefPubMed

89.

Bea JW, Zhao Q, Cauley JA, LaCroix AZ, Bassford T, Lewis CE, et al. Effect of hormone therapy on lean body mass, falls, and fractures: 6-year results from the Women’s Health Initiative hormone trials. Menopause (New York, NY). 2011;18(1):44–52. https://doi.org/10.1097/gme.0b013e3181e3aab1.CrossRef

90.

Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res. 2002;53(3):688–708.CrossRefPubMed

91.

Cacciatore B, Paakkari I, Hasselblatt R, Nieminen MS, Toivonen J, Tikkanen MI, et al. Randomized comparison between orally and transdermally administered hormone replacement therapy regimens of long-term effects on 24-hour ambulatory blood pressure in postmenopausal women. Am J Obstet Gynecol. 2001;184(5):904–9. https://doi.org/10.1067/mob.2001.111246.CrossRefPubMed

92.

Utian WH. Effect of postmenopausal estrogen therapy on diastolic blood pressure and bodyweight. Maturitas. 1978;1(1):3–8.CrossRefPubMed

93.

Lam KK, Hu CT, Ou TY, Yen MH, Chen HI. Effects of oestrogen replacement on steady and pulsatile haemodynamics in ovariectomized rats. Br J Pharmacol. 2002;136(6):811–8. https://doi.org/10.1038/sj.bjp.0704762.CrossRefPubMedPubMedCentral

94.

Colafella KMM, Denton KM. Sex-specific differences in hypertension and associated cardiovascular disease. Nat Rev Nephrol. 2018;14(3):185–201. https://doi.org/10.1038/nrneph.2017.189.CrossRefPubMed

95.

Brussaard HE, Gevers Leuven JA, Frolich M, Kluft C, Krans HM. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia. 1997;40(7):843–9.CrossRefPubMed

96.

Bailey CJ, Ahmed-Sorour H. Role of ovarian hormones in the long-term control of glucose homeostasis. Effects of insulin secretion. Diabetologia. 1980;19(5):475–81.CrossRefPubMed

97.

Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev. 2013;34(3):309–38. https://doi.org/10.1210/er.2012-1055.CrossRefPubMedPubMedCentral

98.

Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994;331(16):1056–61. https://doi.org/10.1056/nejm199410203311604.CrossRefPubMed

99.

Neve A, Corrado A, Cantatore FP. Osteocalcin: skeletal and extra-skeletal effects. J Cell Physiol. 2013;228(6):1149–53. https://doi.org/10.1002/jcp.24278.CrossRefPubMed

100.

Research ASfBaM. Primer on the metabolic bone diseases and disorders of mineral metabolism. 8th ed. Hoboken: Wiley-Blackwell; 2013.

101.

Zoch ML, Abou DS, Clemens TL, Thorek DL, Riddle RC. In vivo radiometric analysis of glucose uptake and distribution in mouse bone. Bone Res. 2016;4:16004. https://doi.org/10.1038/boneres.2016.4.CrossRefPubMedPubMedCentral

102.

Lian JB, Tassinari M, Glowacki J. Resorption of implanted bone prepared from normal and warfarin-treated rats. J Clin Invest. 1984;73(4):1223–6. https://doi.org/10.1172/jci111308.CrossRefPubMedPubMedCentral

103.

Chenu C, Colucci S, Grano M, Zigrino P, Barattolo R, Zambonin G, et al. Osteocalcin induces chemotaxis, secretion of matrix proteins, and calcium-mediated intracellular signaling in human osteoclast-like cells. J Cell Biol. 1994;127(4):1149–58.CrossRefPubMed

104.

Ingram RT, Park YK, Clarke BL, Fitzpatrick LA. Age- and gender-related changes in the distribution of osteocalcin in the extracellular matrix of normal male and female bone. Possible involvement of osteocalcin in bone remodeling. J Clin Invest. 1994;93(3):989–97. https://doi.org/10.1172/jci117106.CrossRefPubMedPubMedCentral

105.

Bao Y, Ma X, Yang R, Wang F, Hao Y, Dou J, et al. Inverse relationship between serum osteocalcin levels and visceral fat area in Chinese men. J Clin Endocrinol Metab. 2013;98(1):345–51. https://doi.org/10.1210/jc.2012-2906.CrossRefPubMed

106.

Zhou M, Ma X, Li H, Pan X, Tang J, Gao Y, et al. Serum osteocalcin concentrations in relation to glucose and lipid metabolism in Chinese individuals. Eur J Endocrinol. 2009;161(5):723–9. https://doi.org/10.1530/eje-09-0585.CrossRefPubMed

107.

Schafer AL, Sellmeyer DE, Schwartz AV, Rosen CJ, Vittinghoff E, Palermo L, et al. Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1–84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). J Clin Endocrinol Metab. 2011;96(12):E1982–9. https://doi.org/10.1210/jc.2011-0587.CrossRefPubMedPubMedCentral

108•.

Knapen MHJ, Jardon KM, Vermeer C. Vitamin K-induced effects on body fat and weight: results from a 3-year vitamin K2 intervention study. Eur J Clin Nutr. 2018;72(1):136–41. https://doi.org/10.1038/ejcn.2017.146. In this randomized placebo-controlled human intervention trial in postmenopausal women, 180 mcg/day of vitamin K2 over 3 years resulted in increased circulating carboxylated osteocalcin, but had no effect on body composition. Additionally, in good responders, vitamin K2 treatment resulted in significantly increased total and human molecular weight adiponectin and decreased abdominal fat mass and estimated viseral adipose tissue area.CrossRefPubMed

109.

Shea MK, Dawson-Hughes B, Gundberg CM, Booth SL. Reducing undercarboxylated osteocalcin with vitamin k supplementation does not promote lean tissue loss or fat gain over 3 years in older women and men: a randomized controlled trial. J Bone Miner Res. 2017;32(2):243–9. https://doi.org/10.1002/jbmr.2989.CrossRefPubMed

110.

Yeap BB, Chubb SA, Flicker L, McCaul KA, Ebeling PR, Beilby JP, et al. Reduced serum total osteocalcin is associated with metabolic syndrome in older men via waist circumference, hyperglycemia, and triglyceride levels. Eur J Endocrinol. 2010;163(2):265–72. https://doi.org/10.1530/eje-10-0414.CrossRefPubMed

111.

Saleem U, Mosley TH Jr, Kullo IJ. Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arterioscler Thromb Vasc Biol. 2010;30(7):1474–8. https://doi.org/10.1161/atvbaha.110.204859.CrossRefPubMedPubMedCentral

112.

Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, Yano S, et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94(1):45–9. https://doi.org/10.1210/jc.2008-1455.CrossRefPubMed

113.

Goliasch G, Blessberger H, Azar D, Heinze G, Wojta J, Bieglmayer C, et al. Markers of bone metabolism in premature myocardial infarction (</= 40 years of age). Bone. 2011;48(3):622–6. https://doi.org/10.1016/j.bone.2010.11.005.CrossRefPubMed

114.

Mansour AG, Hariri E, Daaboul Y, Korjian S, El Alam A, Protogerou AD, et al. Vitamin K2 supplementation and arterial stiffness among renal transplant recipients-a single-arm, single-center clinical trial. J Am Soc Hypertens. 2017;11(9):589–97. https://doi.org/10.1016/j.jash.2017.07.001.CrossRefPubMed

115.

Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130(3):456–69. https://doi.org/10.1016/j.cell.2007.05.047.CrossRefPubMedPubMedCentral

116.

Zanatta LC, Boguszewski CL, Borba VZ, Kulak CA. Osteocalcin, energy and glucose metabolism. Arq Bras Endocrinol Metabol. 2014;58(5):444–51.CrossRefPubMed

117.

Hwang YC, Jeong IK, Ahn KJ, Chung HY. The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects. Diabetes Metab Res Rev. 2009;25(8):768–72. https://doi.org/10.1002/dmrr.1045.CrossRefPubMed

118.

Shea MK, Gundberg CM, Meigs JB, Dallal GE, Saltzman E, Yoshida M, et al. Gamma-carboxylation of osteocalcin and insulin resistance in older men and women. Am J Clin Nutr. 2009;90(5):1230–5. https://doi.org/10.3945/ajcn.2009.28151.CrossRefPubMedPubMedCentral

119.

Diaz-Lopez A, Bullo M, Juanola-Falgarona M, Martinez-Gonzalez MA, Estruch R, Covas MI, et al. Reduced serum concentrations of carboxylated and undercarboxylated osteocalcin are associated with risk of developing type 2 diabetes mellitus in a high cardiovascular risk population: a nested case-control study. J Clin Endocrinol Metab. 2013;98(11):4524–31. https://doi.org/10.1210/jc.2013-2472.CrossRefPubMed

120.

Boucher-Berry C, Speiser PW, Carey DE, Shelov SP, Accacha S, Fennoy I, et al. Vitamin D, osteocalcin, and risk for adiposity as comorbidities in middle school children. J Bone Miner Res. 2012;27(2):283–93. https://doi.org/10.1002/jbmr.550.CrossRefPubMed

121.

Sukumar D, Shapses SA, Schneider SH. Vitamin D supplementation during short-term caloric restriction in healthy overweight/obese older women: effect on glycemic indices and serum osteocalcin levels. Mol Cell Endocrinol. 2015;410:73–7. https://doi.org/10.1016/j.mce.2015.01.002.CrossRefPubMedPubMedCentral

122.

Thrailkill KM, Jo CH, Cockrell GE, Moreau CS, Lumpkin CK Jr, Fowlkes JL. Determinants of undercarboxylated and carboxylated osteocalcin concentrations in type 1 diabetes. Osteoporos Int. 2012;23(6):1799–806. https://doi.org/10.1007/s00198-011-1807-7.CrossRefPubMed

123.

Masrour Roudsari J, Mahjoub S. Quantification and comparison of bone-specific alkaline phosphatase with two methods in normal and paget’s specimens. Caspian J Intern Med. 2012;3(3):478–83.PubMedPubMedCentral

124.

Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Luftner D. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer. Anticancer Res. 2007;27(4a):1853–62.PubMed

125.

Greenblatt MB, Tsai JN, Wein MN. Bone turnover markers in the diagnosis and monitoring of metabolic bone disease. Clin Chem. 2017;63(2):464–74. https://doi.org/10.1373/clinchem.2016.259085.CrossRefPubMed

126.

Ishimura E, Okuno S, Okazaki H, Norimine K, Yamakawa K, Yamakawa T, et al. Significant association between bone-specific alkaline phosphatase and vascular calcification of the hand arteries in male hemodialysis patients. Kidney Blood Press Res. 2014;39(4):299–307. https://doi.org/10.1159/000355807.CrossRefPubMed

127.

Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int. 2000;66(2):100–3.CrossRefPubMed

128.

Viljakainen H, Ivaska KK, Paldanius P, Lipsanen-Nyman M, Saukkonen T, Pietilainen KH, et al. Suppressed bone turnover in obesity: a link to energy metabolism? A case-control study. J Clin Endocrinol Metab. 2014;99(6):2155–63. https://doi.org/10.1210/jc.2013-3097.CrossRefPubMed

129.

Kucukalic-Selimovic E, Valjevac A, Hadzovic-Dzuvo A. The utility of procollagen type 1 N-terminal propeptide for the bone status assessment in postmenopausal women. Bosnian J Basic Med Sci. 2013;13(4):259–65. https://doi.org/10.17305/bjbms.2013.2337.CrossRef

130.

Cheung CL, Tan KC, Lam KS, Cheung BM. The relationship between glucose metabolism, metabolic syndrome, and bone-specific alkaline phosphatase: a structural equation modeling approach. J Clin Endocrinol Metab. 2013;98(9):3856–63. https://doi.org/10.1210/jc.2013-2024.CrossRefPubMed

131.

Iba K, Takada J, Yamashita T. The serum level of bone-specific alkaline phosphatase activity is associated with aortic calcification in osteoporosis patients. J Bone Miner Metab. 2004;22(6):594–6. https://doi.org/10.1007/s00774-004-0528-9.CrossRefPubMed

132.

Fukushima N, Suzuki A, Fukushima K, Tanaka Y, Sato Y, Shiga T, et al. Impact of the serum bone-specific alkaline phosphatase level at the initiation of hemodialysis therapy for end-stage renal disease on cardiovascular events. IJC Metab Endocr. 2014;4:58–62.CrossRef

133.

Drechsler C, Verduijn M, Pilz S, Krediet RT, Dekker FW, Wanner C, et al. Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol. 2011;6(7):1752–9. https://doi.org/10.2215/cjn.10091110.CrossRefPubMed

134.

Newton A, Hanks L, Judd S, Wallace S, Durant N, Casazza K. Low HDL cholesterol may lead to disruption of bone (re) modeling in obese early pubertal girls. Int J Orthop. 2015;2(3).

135.

Anderson JL, Vanwoerkom RC, Horne BD, Bair TL, May HT, Lappe DL, et al. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? Am Heart J. 2011;162(2):331–9.e2. https://doi.org/10.1016/j.ahj.2011.05.005.CrossRefPubMed

136.

Saber LM, Mahran HN, Baghdadi HH, Al Hawsawi ZM. Interrelationship between bone turnover markers, calciotropic hormones and leptin in obese Saudi children. Eur Rev Med Pharmacol Sci. 2015;19(22):4332–43.PubMed

137.

Kanazawa I, Yamaguchi T, Yamauchi M, Yamamoto M, Kurioka S, Yano S, et al. Adiponectin is associated with changes in bone markers during glycemic control in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94(8):3031–7. https://doi.org/10.1210/jc.2008-2187.CrossRefPubMed

138.

Szulc P, Varennes A, Delmas PD, Goudable J, Chapurlat R. Men with metabolic syndrome have lower bone mineral density but lower fracture risk--the MINOS study. J Bone Miner Res. 2010;25(6):1446–54. https://doi.org/10.1002/jbmr.13.CrossRefPubMed

139.

Wang J, Yan DD, Hou XH, Bao YQ, Hu C, Zhang ZL, et al. Association of bone turnover markers with glucose metabolism in Chinese population. Acta Pharmacol Sin. 2017;38(12):1611–7. https://doi.org/10.1038/aps.2017.23.CrossRefPubMedPubMedCentral

140.

Ogata M, Ide R, Takizawa M, Tanaka M, Tetsuo T, Sato A, et al. Association between basal metabolic function and bone metabolism in postmenopausal women with type 2 diabetes. Nutrition (Burbank, Los Angeles County, Calif). 2015;31(11–12):1394–401. https://doi.org/10.1016/j.nut.2015.06.012.CrossRef

141.

Oz SG, Guven GS, Kilicarslan A, Calik N, Beyazit Y, Sozen T. Evaluation of bone metabolism and bone mass in patients with type-2 diabetes mellitus. J Natl Med Assoc. 2006;98(10):1598–604.PubMedPubMedCentral

142.

Gerdhem P, Isaksson A, Akesson K, Obrant KJ. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int. 2005;16(12):1506–12. https://doi.org/10.1007/s00198-005-1877-5.CrossRefPubMed

143.

Xuan Y, Sun LH, Liu DM, Zhao L, Tao B, Wang WQ, et al. Positive association between serum levels of bone resorption marker CTX and HbA1c in women with normal glucose tolerance. J Clin Endocrinol Metab. 2015;100(1):274–81. https://doi.org/10.1210/jc.2014-2583.CrossRefPubMed

144.

Hamilton EJ, Rakic V, Davis WA, Paul Chubb SA, Kamber N, Prince RL, et al. A five-year prospective study of bone mineral density in men and women with diabetes: the Fremantle Diabetes Study. Acta Diabetol. 2012;49(2):153–8. https://doi.org/10.1007/s00592-011-0324-7.CrossRefPubMed

Title: The Endocrine Role of Bone in Cardiometabolic Health
Authors: Rosemary DeLuccia
May Cheung
Rohit Ramadoss
Abeer Aljahdali
Deeptha Sukumar
Publication date: 01-09-2019
Publisher: Springer US
Keywords: Insulins
Insulins
Estrogens
Estradiol
Published in: Current Nutrition Reports / Issue 3/2019
Electronic ISSN: 2161-3311
DOI: https://doi.org/10.1007/s13668-019-00286-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2019

Nutritional Metabolomics in Cancer Epidemiology: Current Trends, Challenges, and Future Directions

The Influence of Sedentary Behavior on Cancer Risk: Epidemiologic Evidence and Potential Molecular Mechanisms

Does Alcohol Use Affect Cancer Risk?

Carbohydrate Nutrition and the Risk of Cancer

Nutrition and Metabolic Profiles in the Natural History of Dementia: Recent Insights from Systems Biology and Life Course Epidemiology

Vitamin D3 from Ultraviolet-B Exposure or Oral Intake in Relation to Cancer Incidence and Mortality

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage